Varaico: Literature-Extracted Genetic Variants

Gene:MAP2K1
Variant:p.I103del1
Back to variants list

MAP2K1

NM_002755.4:p.I103del1

Associated Papers

Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma.

Fu F et al.

Cell Research, 2025

Class 3 MAPK Mutation in Langerhans cell histiocytosis and Trametinib-Reporting Two Contrarian Responses.

Wojciechowska N et al.

Pediatric Blood & Cancer, 2025

Mechanisms of resistance to RET-directed therapies.

Clifton-Bligh RJ

Endocrine-related Cancer, 2025

39655713 (PubMed )
Supplement: supplementary_materials.pdf

RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report.

Pishdad R et al.

Frontiers in Oncology, 2024

Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report.

Dirven I et al.

Frontiers in Medicine, 2024

Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis.

Roeser A et al.

Journal of Hematology, 2022

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.

Tanaka N et al.

Cancer Discovery, 2021

Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.

Tóth B et al.

Virchows Archiv : an International Journal of Pathology, 2020

How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study.

Liu Y et al.

Journal of Biomolecular Structure & Dynamics, 2020

A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors.

Wang C et al.

Journal of Gastrointestinal Oncology, 2019

Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.

Azorsa DO et al.

Pediatric Blood & Cancer, 2018

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.

Ma P et al.

Nature Communications, 2017

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Chakraborty R et al.

Blood, 2014

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."